Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a

Fiche publication

Date publication

août 2020

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr GHIRINGHELLI François , Mme TRUNTZER Caroline , Dr LIMAGNE Emeric , Dr FUMET Jean-David , Dr THIBAUDIN Marion

Tous les auteurs :
Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32778095

Résumé

Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T) is a mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This study is designed to evaluate the efficacy of combination of olaparib, durvalumab and tremelimumab in patients with a solid tumors with a mutation in homologous gene repair.